NGM BIOPHARMACEUTICALS INC Annual Operating Income (Loss) in USD from 2017 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Ngm Biopharmaceuticals Inc quarterly/annual Operating Income (Loss) history and growth rate from 2017 to 2023.
  • Ngm Biopharmaceuticals Inc Operating Income (Loss) for the quarter ending December 31, 2023 was -$29.7M, a 22.5% increase year-over-year.
  • Ngm Biopharmaceuticals Inc Operating Income (Loss) for the twelve months ending December 31, 2023 was -$151M, a 8.89% increase year-over-year.
  • Ngm Biopharmaceuticals Inc annual Operating Income (Loss) for 2023 was -$151M, a 8.89% increase from 2022.
  • Ngm Biopharmaceuticals Inc annual Operating Income (Loss) for 2022 was -$166M, a 37.7% decline from 2021.
  • Ngm Biopharmaceuticals Inc annual Operating Income (Loss) for 2021 was -$121M, a 16.2% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$151M +$14.8M +8.89% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-11
2022 -$166M -$45.6M -37.7% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-11
2021 -$121M -$16.9M -16.2% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-11
2020 -$104M -$54.5M -110% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 -$49.3M -$45M -1044% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
2018 -$4.31M +$13.1M +75.2% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-15
2017 -$17.4M Jan 1, 2017 Dec 31, 2017 10-K 2020-03-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.